Jump to content

All Activity

This stream auto-updates

  1. Yesterday
  2. Sorry I missed this discussion, it was very interesting. Since an email sent out re-opened this discussion I would just make a brief comment. HDN is a terrible outcome for the child especially, and also the mother and family. Not using antenatal RhIg is medical negligence. Not giving a potential D negative female/mother RhIg is close behind. It has always been a challenge with our anti-D reagents to deal with interpretation of weak reactivity and females of "child-bearing" age. And our testing methods have improved over the years. However, with the advances in molecular biology is ser
  3. We use a regular irradiator, only stores the last 200 runs. When you say Raycell data, is there data other than the unit info? We print ours out and review each run. We don't back anything up.
  4. Hello all. I have Vision and we have two of the Ortho Sera reagents that we use, the weak D and anti-K. The problem with doing antigen typing for us is that we don't do enough of it to get the Ortho antigen typing cards. If we got one sleeve of Anti-E cards we'd probably have to throw some away at the expiration date. Same with any of the other Rh cards they offer. What would be ideal for us and probably a lot of places is Ortho Sera for Rh antigens because the antisera has a much longer expiration date - 18 to 24 months I think. I asked our rep if they planned on producing those and he said t
  5. Last week
  6. We have dedicated staff. There were too many errors otherwise.
  7. Wow. I didn't realise how lucky we are at my hospital. We process around 7,000 samples a year, so not a large facility. It is not a lack of expertise that stops us doing elutions/titres/adsorptions rather that it would not make financial sense for us to. We have 4 full-time transfusion specialists for routine (9-5) hours. Outside of these times is covered by multidisciplinary on-call. Any biomedical scientist in the pathology department can join the rota. On call samples are processed in haematology, transfusion, biochemistry and a few micro tests by the lone worker. Traini
  8. I just answered this question. My Score PASS  
  9. I searched the operator's manual for info and also contacted Immucor about carryover. They basically said there could be carryover but it would be extremely rare since the patient's titer would have to be higher than 5120 and humans do not reach that level. So I decided to use the CAP JAT or J series and test 2 or up to 5 in the same run. The positives are generally pretty strong (4+) and there is always at least 1 negative in the bunch. I also look thru the past patient testing and find at least 3 strong positive (3-4+) patients with either a negative patient in the same run or the next
  10. I just answered this question. My Score PASS  
  11. Thanks for the feed backs. Our facility risk management reports the fatalities to the state and the blood bank to the FDA, so we had to add to the blood bank policy that risk management would notify the state.
  12. There are actually 2 scenarios in this string: 1. Issuing plasma that you know is incompatible with a patient (i.e. ABO is verified) and 2. Issuing plasma when you haven't verified the patient's ABO with a current sample. For #1: If you are in the US, the CDC/FDA wants us to treat all incompatible plasma as if it were 'Emergency Release' so use your Emergency Release Protocol. For #2: If your patient's ABO Group has not been verified (e.g. sample tested using your protocol for verification), use your Emergency Release Protocol.
  13. We have found that washing the cells 3x with 37C saline will resolve this situation in just about every case where RT Saline wash doesn't help. If you are using Gel, there may be other reasons for the extraneous 'positive results' using your patient cells, e.g. sickled cells, acanthrocytes, protein coating. So, those must also be considered.
  14. Blood Transfusion Therapy in Haemoglobinopathies Blood Transfusion Therapy in Haemoglobinopathies This question was submitted by forum member, Malcolm Needs. Any errors are those of the site admin, not Malcolm. Blood Transfusion Therapy for Haemoglobinopathies.pptx Submitter Cliff Category BloodBankTalk Submitted 09/15/2020  
    • quizzes_questions_pl
    • quizzes_players_pl
    Blood Transfusion Therapy in Haemoglobinopathies This question was submitted by forum member, Malcolm Needs. Any errors are those of the site admin, not Malcolm. Blood Transfusion Therapy for Haemoglobinopathies.pptx
  15. Unsure if you still need a reply: You should print/review or store/review your data at regular intervals.
  16. The issue is when host (instrument) sends query to WellSky. WellSky will only send back message at patient level. It does not have capability to send specimen level message yet. You will have to find a workaround. Either program the instrument to run and report your ABO confirm first or run and report type and screen.
  17. Tests on the adsorbed serum (with ZZAP-treated cells) give confidence that the are no underlying alloantibodies to common antigens. However, the use of allogeneic cells risks removal of a cold-reactive alloantibody to a high incidence antigen, e.g. anti-Vel, -PP1pK. A low risk, but still concerning. Does you facility also test the ZZAP-treated patient cells (now presumably DAT-negative) back against the patient's own serum ? This is ultimate proof that the cold-reactive antibody is an AUTOantibody and adds more confidence in the results of the adsorption with allogenic cells. I may b
  18. Is anyone else using Wellsky and the Ortho Vision? We are having issues with the query bringing in ALL the tests on the patient verses the just the test that is "tied" to that accession/specimen number.
  19. Would you be willing to share your validation plan? Thanks!
  1. Load more activity
  • Advertisement

  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.